Carbon Ion Beam Reirradiation in Recurrent High-Grade Glioma
Received 30 May 2019
Accepted for publication 23 October 2019
Published 28 January 2020 Volume 2020:12 Pages 633—639
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sanjeev Srivastava
Fabian Eberle, 1–4 Stefan Lautenschläger, 4 Rita Engenhart-Cabillic, 1, 3, 4 Alexandra D Jensen, 5 Barbara Carl, 6 Marco Stein, 7 Jürgen Debus, 1–3, 8–11 Henrik Hauswald 1–4, 8, 10, 11
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; 2Heidelberg Institute for Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), Heidelberg, Germany; 3Marburg Ion-Beam Therapy Center (MIT), Department of Radiation Oncology, Heidelberg University Hospital, Marburg, Germany; 4Department of Radiation Oncology, Marburg University Hospital, Marburg, Germany; 5Department of Radiation Oncology, Gießen University Hospital, Gießen, Germany; 6Department of Neurosurgery, Marburg University Hospital, Marburg, Germany; 7Department of Neurosurgery, Gießen University Hospital, Gießen, Germany; 8Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; 9German Cancer Consortium (DKTK), Heidelberg, Germany; 10National Center for Tumor Diseases (NCT), Heidelberg, Germany; 11Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Correspondence: Henrik Hauswald
Department of Radiation Oncology, Heidelberg University Hospital, INF 400, Heidelberg 69120, Germany
Background: Patients with recurrent glioma after prior radiotherapy have a poor prognosis. Carbon ion beam radiotherapy offers highly conformal dose distributions and more complex biological radiation effects eventually resulting in optimized normal tissue sparing and improved outcome. The aim of this study was to analyze toxicity, local control and overall survival after reirradiation of recurrent high-grade glioma with carbon ion radiotherapy.
Methods: Between 10/2015 and 12/2018, 30 patients (median age: 59 years) with recurrent high-grade glioma were reirradiated with carbon ion beams and retrospectively analyzed. Diagnosis of recurrent glioma was based on magnetic resonance imaging. Thirteen patients had repeated resection prior to reirradiation and 24 patients underwent additional chemotherapy. The median initial radiation dose was 60 Gy and the median time interval between the initial and repeated radiotherapy was 10 months. The reirradiation dose was 45 Gy (relative biological effectiveness) applied in 15 fractions. All patients received regular follow-up imaging after reirradiation. Kaplan-Meier estimation, log rank test and Cox regression analysis were used for statistical assessment.
Results: Applying common toxicity criteria, there were no grade 5 or 4 adverse events, while 8 patients showed grade 3 adverse events. The median follow-up after reirradiation was 11 months and the median overall survival after diagnosis of recurrent high-grade glioma was 13 months. The 6-, 12- and 24-month overall survival rates after diagnosis of recurrent high-grade glioma were 76%, 50% and 19%, respectively. Upon multivariate Cox regression analysis, a Ki67 score of the initial tumor histology of less than 20% was prognostic. Repeated resection or chemotherapy for the recurrent disease did not result in significantly prolonged survival.
Conclusion: Carbon ion reirradiation in recurrent high-grade glioma is safe and feasible. No radiation-associated grade 4 toxicities were documented and treatment was tolerated well.
Keywords: glioma, glioblastoma, reirradiation, carbon ion beam therapy, C12, particle beam therapy, radiotherapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]